{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Tumor+of+Urinary+Bladder&page=4",
    "query": {
      "condition": "Malignant Tumor of Urinary Bladder",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 196,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Tumor+of+Urinary+Bladder&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Tumor+of+Urinary+Bladder&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T05:53:50.860Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04774952",
      "title": "Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "RMC-5552",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2021-04-07",
      "completion_date": "2024-06-28",
      "has_results": false,
      "last_update_posted_date": "2025-04-15",
      "last_synced_at": "2026-10-06T05:53:50.860Z",
      "location_count": 8,
      "location_summary": "Irvine, California • Sacramento, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04774952"
    },
    {
      "nct_id": "NCT01007058",
      "title": "Markers of Response to Intravesical Bladder Cancer Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2005-06",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2016-12-07",
      "last_synced_at": "2026-10-06T05:53:50.860Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01007058"
    },
    {
      "nct_id": "NCT06310759",
      "title": "Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Tampere University Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 3000,
      "start_date": "2024-01-08",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-10-06T05:53:50.860Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06310759"
    },
    {
      "nct_id": "NCT04501913",
      "title": "Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage 0 Gastric Cancer AJCC v8",
        "Clinical Stage I Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage I Gastric Cancer AJCC v8",
        "Clinical Stage II Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage II Gastric Cancer AJCC v8",
        "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IIA Gastric Cancer AJCC v8",
        "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IIB Gastric Cancer AJCC v8",
        "Clinical Stage III Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage IVA Gastric Cancer AJCC v8",
        "Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage IVB Gastric Cancer AJCC v8",
        "Hepatobiliary Neoplasm",
        "Malignant Digestive System Neoplasm",
        "Malignant Female Reproductive System Neoplasm",
        "Malignant Genitourinary System Neoplasm",
        "Malignant Neoplasm",
        "Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage 0 Gastric Cancer AJCC v8",
        "Pathologic Stage I Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage I Gastric Cancer AJCC v8",
        "Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IA Gastric Cancer AJCC v8",
        "Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IB Gastric Cancer AJCC v8",
        "Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage II Gastric Cancer AJCC v8",
        "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IIA Gastric Cancer AJCC v8",
        "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IIB Gastric Cancer AJCC v8",
        "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage III Gastric Cancer AJCC v8",
        "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IIIA Gastric Cancer AJCC v8",
        "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IIIB Gastric Cancer AJCC v8",
        "Pathologic Stage IIIC Gastric Cancer AJCC v8",
        "Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IV Gastric Cancer AJCC v8",
        "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Stage 0 Colorectal Cancer AJCC v8",
        "Stage 0a Bladder Cancer AJCC v8",
        "Stage 0is Bladder Cancer AJCC v8",
        "Stage I Bladder Cancer AJCC v8",
        "Stage I Cervical Cancer AJCC v8",
        "Stage I Colorectal Cancer AJCC v8",
        "Stage I Ovarian Cancer AJCC v8",
        "Stage I Prostate Cancer AJCC v8",
        "Stage I Renal Cell Cancer AJCC v8",
        "Stage I Uterine Corpus Cancer AJCC v8",
        "Stage IA Cervical Cancer AJCC v8",
        "Stage IA Ovarian Cancer AJCC v8",
        "Stage IA Uterine Corpus Cancer AJCC v8",
        "Stage IA1 Cervical Cancer AJCC v8",
        "Stage IA2 Cervical Cancer AJCC v8",
        "Stage IB Cervical Cancer AJCC v8",
        "Stage IB Ovarian Cancer AJCC v8",
        "Stage IB Uterine Corpus Cancer AJCC v8",
        "Stage IB1 Cervical Cancer AJCC v8",
        "Stage IB2 Cervical Cancer AJCC v8",
        "Stage IC Ovarian Cancer AJCC v8",
        "Stage II Bladder Cancer AJCC v8",
        "Stage II Cervical Cancer AJCC v8",
        "Stage II Colorectal Cancer AJCC v8",
        "Stage II Ovarian Cancer AJCC v8",
        "Stage II Prostate Cancer AJCC v8",
        "Stage II Renal Cell Cancer AJCC v8",
        "Stage II Uterine Corpus Cancer AJCC v8",
        "Stage IIA Cervical Cancer AJCC v8",
        "Stage IIA Colorectal Cancer AJCC v8",
        "Stage IIA Ovarian Cancer AJCC v8",
        "Stage IIA Prostate Cancer AJCC v8",
        "Stage IIA1 Cervical Cancer AJCC v8",
        "Stage IIA2 Cervical Cancer AJCC v8",
        "Stage IIB Cervical Cancer AJCC v8",
        "Stage IIB Colorectal Cancer AJCC v8",
        "Stage IIB Ovarian Cancer AJCC v8",
        "Stage IIB Prostate Cancer AJCC v8",
        "Stage IIC Colorectal Cancer AJCC v8",
        "Stage IIC Prostate Cancer AJCC v8",
        "Stage III Bladder Cancer AJCC v8",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Prostate Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage III Uterine Corpus Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8",
        "Stage IIIA Cervical Cancer AJCC v8",
        "Stage IIIA Colorectal Cancer AJCC v8",
        "Stage IIIA Ovarian Cancer AJCC v8",
        "Stage IIIA Prostate Cancer AJCC v8",
        "Stage IIIA Uterine Corpus Cancer AJCC v8",
        "Stage IIIA1 Ovarian Cancer AJCC v8",
        "Stage IIIA2 Ovarian Cancer AJCC v8",
        "Stage IIIB Bladder Cancer AJCC v8",
        "Stage IIIB Cervical Cancer AJCC v8",
        "Stage IIIB Colorectal Cancer AJCC v8",
        "Stage IIIB Ovarian Cancer AJCC v8",
        "Stage IIIB Prostate Cancer AJCC v8",
        "Stage IIIB Uterine Corpus Cancer AJCC v8",
        "Stage IIIC Colorectal Cancer AJCC v8",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IIIC Prostate Cancer AJCC v8",
        "Stage IIIC Uterine Corpus Cancer AJCC v8",
        "Stage IIIC1 Uterine Corpus Cancer AJCC v8",
        "Stage IIIC2 Uterine Corpus Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Prostate Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IV Uterine Corpus Cancer AJCC v8",
        "Stage IVA Bladder Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVB Bladder Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Patient Monitoring",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2019-12-24",
      "completion_date": "2025-10-17",
      "has_results": false,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-10-06T05:53:50.860Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04501913"
    },
    {
      "nct_id": "NCT06529822",
      "title": "Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Muscle-Invasive Bladder Carcinoma",
        "Gastroesophageal Adenocarcinoma",
        "Melanoma",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Synthetic long peptide personalized cancer vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        },
        {
          "name": "Signatera or Altera testing",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2025-03-20",
      "completion_date": "2034-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-06T05:53:50.860Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • St Louis, Missouri • Columbus, Ohio",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06529822"
    },
    {
      "nct_id": "NCT06022029",
      "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Diffuse Large B Cell Lymphoma",
        "Follicular Lymphoma",
        "Lymphoma, Non-Hodgkin",
        "Mantle Cell Lymphoma",
        "Bladder Cancer",
        "Uveal Melanoma, Recurrent",
        "Cervix Cancer",
        "Carcinoma in Situ",
        "Head and Neck Squamous Cell Carcinoma",
        "Skin Cancer",
        "Metastatic Cancer",
        "Tumor, Solid",
        "Tumor Recurrence"
      ],
      "interventions": [
        {
          "name": "ONM-501",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoNano Medicine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 168,
      "start_date": "2023-10-13",
      "completion_date": "2026-08-29",
      "has_results": false,
      "last_update_posted_date": "2025-12-24",
      "last_synced_at": "2026-10-06T05:53:50.860Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06022029"
    },
    {
      "nct_id": "NCT04940299",
      "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Locally Advanced Bladder Carcinoma",
        "Locally Advanced Bladder Urothelial Carcinoma",
        "Locally Advanced Lung Non-Small Cell Carcinoma",
        "Locally Advanced Renal Pelvis Carcinoma",
        "Locally Advanced Renal Pelvis Urothelial Carcinoma",
        "Locally Advanced Ureter Urothelial Carcinoma",
        "Locally Advanced Urethral Urothelial Carcinoma",
        "Malignant Solid Neoplasm",
        "Metastatic Bladder Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Melanoma",
        "Metastatic Renal Pelvis Urothelial Carcinoma",
        "Metastatic Ureter Urothelial Carcinoma",
        "Metastatic Urethral Carcinoma",
        "Metastatic Urethral Urothelial Carcinoma",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Stage III Bladder Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage III Urethral Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Bladder Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v6",
        "Stage IV Renal Pelvis Cancer AJCC v8",
        "Stage IV Ureter Cancer AJCC v8",
        "Stage IV Urethral Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tocilizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2021-09-23",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-06T05:53:50.860Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04940299"
    },
    {
      "nct_id": "NCT03740256",
      "title": "Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Cancer of the Salivary Gland",
        "Lung Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Colorectal Cancer",
        "Pancreatic Adenocarcinoma",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "CAdVEC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2020-12-14",
      "completion_date": "2038-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-10-06T05:53:50.860Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03740256"
    },
    {
      "nct_id": "NCT03629756",
      "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Breast Cancer",
        "Colorectal Cancer",
        "Melanoma",
        "Bladder Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Merkel Cell Carcinoma",
        "GastroEsophageal Cancer",
        "Renal Cell Carcinoma",
        "Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Etrumadenant",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2018-07-24",
      "completion_date": "2021-09-03",
      "has_results": false,
      "last_update_posted_date": "2024-05-24",
      "last_synced_at": "2026-10-06T05:53:50.860Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03629756"
    },
    {
      "nct_id": "NCT06995898",
      "title": "The Vanguard Study: Testing a New Way to Screen for Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bladder Carcinoma",
        "Breast Carcinoma",
        "Colorectal Carcinoma",
        "Esophageal Carcinoma",
        "Gastric Carcinoma",
        "Liver Carcinoma",
        "Lung Carcinoma",
        "Malignant Solid Neoplasm",
        "Ovarian Carcinoma",
        "Pancreatic Carcinoma",
        "Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Device Usage",
          "type": "DEVICE"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        },
        {
          "name": "Multi-Cancer Detection Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 24000,
      "start_date": "2025-06-18",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-06T05:53:50.860Z",
      "location_count": 44,
      "location_summary": "Pleasanton, California • Cheyenne Wells, Colorado • Denver, Colorado + 36 more",
      "locations": [
        {
          "city": "Pleasanton",
          "state": "California"
        },
        {
          "city": "Cheyenne Wells",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06995898"
    }
  ]
}